vTv Therapeutics Inc.
4170 Mendenhall Oaks Parkway
High Point
North Carolina
27265
United States
Tel: 336-841-0300 ext 100
Fax: 336-841-0310
Website: http://vtvtherapeutics.com/
113 articles with vTv Therapeutics Inc.
-
vTv Therapeutics to Participate at the 6th World Psoriasis & Psoriatic Arthritis Conference with Poster Presentation on HPP737
6/29/2021
vTv Therapeutics Inc. today announced that it will be presenting data from the clinical development of HPP737 as a treatment for psoriasis in a poster presentation at the 6th World Psoriasis & Psoriatic Arthritis Conference held virtually June 30 – July 3, 2021 in Stockholm, Sweden.
-
vTv Therapeutics and Cantex Pharmaceuticals Announce Strategic Licensing Agreement for Development and Commercialization of Azeliragon for Treatment of Cancer
6/22/2021
- vTv Therapeutics Inc. (“vTv”, Nasdaq:VTVT) and Cantex Pharmaceuticals, Inc. (“Cantex”) today announced that they have entered into a licensing agreement under which Cantex has obtained exclusive worldwide rights to develop and commercialize azeliragon, vTv’s novel antagonist of RAGE (the receptor for advanced glycation endproducts).
-
Cantex forges a licensing deal with vTv Therapeutics and intends to evaluate the vTv drug as a potential treatment for several cancer-related issues.
-
vTv Therapeutics Announces 2021 First Quarter Financial Results and Provides Corporate Update
5/5/2021
vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the first quarter ended March 31, 2021, and provided an update on the progress of its clinical programs.
-
vTv Therapeutics Receives FDA Breakthrough Therapy Designation for TTP399 for the Treatment of Type 1 Diabetes
4/13/2021
vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and psoriasis, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for TTP399 as an adjunctive therapy to insulin for the treatment of type 1 diabetes.
-
The U.S. Food and Drug Administration (FDA) granted vTv Therapeutics’ TTP399 Breakthrough Therapy designation for type 1 diabetes. This designation provides companies more support and the possibility of shorter development and review timelines.
-
TTP399 SimpliciT-1 Study Results to be presented at a scientific symposium in celebration of the 100th anniversary of the discovery of insulin
4/12/2021
vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and inflammatory diseases, today announced that results from the JDRF-supported SimpliciT-1 Study will be presented at A Scientific Symposium:
-
vTv Therapeutics Announces Issuance of U.S. Patent Covering Methods of Treatment Using TTP399
3/23/2021
vTv Therapeutics Inc. (Nasdaq: VTVT) announced today that the U.S. Patent and Trademark Office has issued a patent with claims protecting methods of treatment using TTP399, the company’s oral glucokinase activator. The patent number is 10,952,993 (‘993 Patent).
-
The life sciences industry is a bustling beehive of activity. Here’s a quick compilation of some of today’s newsworthy announcements.
-
vTv Therapeutics Announces Initiation of Study Evaluating TTP399’s Potential to Reduce Risk of Diabetic Ketoacidosis in Patients with Type 1 Diabetes
3/18/2021
vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and inflammatory diseases, today announced the initiation of a mechanistic study exploring the effects of TTP399 on ketone body formation during a period of insulin withdrawal in people with type 1 diabetes.
-
vTv Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
3/8/2021
vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and inflammatory diseases, today announced its participation in the H.C. Wainwright Global Life Sciences Conference held virtually March 9-10, 2021
-
vTv Therapeutics Announces 2020 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
2/24/2021
vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the fourth quarter and year ended December 31, 2020, and provided an update on the progress of its clinical programs.
-
vTv Therapeutics Announces Publication in Diabetes Care of Results from SimpliciT-1 Study of TTP399 in Patients with Type 1 Diabetes
2/23/2021
Results found a clinically meaningful decrease in frequency of severe and symptomatic hypoglycemia in addition to statistically significant reductions in HbA1c
-
vTv Therapeutics Announces Initiation of Multiple Ascending Dose Study of HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis
2/17/2021
Phase 1 multiple ascending dose study to evaluate safety of HPP737 in healthy volunteers and inform dose selection for phase 2 planned for 2H 2021 Strategic Partner in Asia and Pacific Rim, Newsoara Biopharma, has initiated a phase 2 study in COPD in China
-
vTv Therapeutics to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access Event Virtually
1/6/2021
vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for type 1 diabetes and inflammatory diseases, today announced that it is participating in the LifeSci Partners 10 th Annual Healthcare Corporate Access Event held virtually from January 11-14 2021. Company management will be conducting one-on-one virtual meetings during the week of the conference
-
Clinical Catch-Up: December 14-18
12/21/2020
Many companies appear to be getting their clinical trial news updated ahead of the holidays. Here’s a look. -
vTv Therapeutics, based in High Point, North Carolina, announced that its Phase II Elevage study of azeliragon in mild Alzheimer’s disease and type 2 diabetes failed to hit its primary objective.
-
vTv Therapeutics Announces Licensing Agreement for Novel Nrf2 Activator to Anteris Bio
12/15/2020
vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that vTv Therapeutics LLC (“vTv”) has entered into a licensing agreement with Anteris Bio for worldwide rights to vTv’s novel clinical-stage Nrf2 activator compound, HPP971. Anteris Bio, a newly-formed portfolio company of Aditum Bio, the biotech investment firm co-founded in 2019 by former Novartis CEO Joe Jimenez and former President of the Novartis Institutes for BioMedical Research (NI
-
vTv Therapeutics has provided worldwide rights for its novel clinical-stage Nrf2 activator compound, HPP971, to newly formed Anteris Bio.
-
vTv Therapeutics Announces Common Stock Purchase Agreement for up to $47 Million with Lincoln Park Capital
11/24/2020
vTv Therapeutics Inc. announced it has entered into a common stock purchase agreement for up to $47 million with Lincoln Park Capital Fund, LLC, a Chicago-based institutional investor.